Advanced Sarcoma, Metastatic Sarcoma, Soft Tissue Sarcoma
Conditions
Keywords
Tracon, STS, LMS, DDLS, ASPS, envafolimab, YH001, CTLA-4, PD-L1, chondrosarcoma
Brief summary
This is a multicenter, open label, Phase 1/2 study of YH001 initially given in combination with envafolimab, and then given in combination with envafolimab plus doxorubicin in patients with advanced or metastatic sarcoma, followed by Phase 2 cohorts of patients with select histologies of advanced or metastatic sarcoma.
Interventions
Sponsors
Tracon Pharmaceuticals Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically confirmed advanced or metastatic sarcoma patients without UPS or MFS who are refractory to or intolerant to standard treatments for their disease. 2. Histologically confirmed advanced or metastatic sarcoma patients without UPS or MFS who have not received any immune checkpoint inhibitors or doxorubicin, and with histology for which doxorubicin is considered a reasonable treatment option (for Cohort 1B, 2B and Expanded Cohort 1B and/or 2B) 3. Measurable disease by RECIST 1.1 4. Age ≥ 18 years 5. Adequate organ function 6. Left ventricular ejection fraction (LVEF) as measured by echo or multigated acquisition scan of \> 50% (for patients to receive doxorubicin) 7. Willingness and ability to consent for self to participate in study 8. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures 9. Men who are sterile or agree to use a condom with spermicide . 10. Women of non-child bearing potential due to surgical sterilization or medically-documented ovarian failure confirmed by medical history, or women of child bearing potential who test negative for pregnancy at time of enrollment and agree to use at least 2 acceptable methods of birth control
Exclusion criteria
1. Gastrointestinal stromal tumor (GIST) or desmoid tumors 2. Condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days prior to enrollment 3. Known allergy to any component of any study drug that the patient would receive if enrolled into this study 4. Prior T-cell or NK-cell therapy 5. Prior pericardial or mediastinal radiation (for patients to receive doxorubicin) 6. Acute coronary syndromes within 6 months of enrollment 7. Women who are pregnant or breast feeding 8. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Phase 1: Determine recommended phase 2 dose of YH001 in combination with Envafolimab | 8 months | Evaluate safety and tolerability and determine the recommended Phase 2 dose (RP2D) of YH001 when given with envafolimab dosed SC every 3 weeks in patients with advanced or metastatic sarcoma who are refractory to or intolerant to other available therapies. |
| Phase 1: Determine recommended phase 2 dose of YH001 in combination with Envafolimab with Doxorubicin | 8 months | Evaluate safety and tolerability and determine RP2D of YH001 in combination with envafolimab dosed SC every 3 weeks and doxorubicin dosed every three weeks in patients with advanced or metastatic sarcoma who have not received doxorubicin and are refractory to or intolerant to other available therapies. |
| Phase 2: Determine the objective response rate (ORR) of YH001 in combination with Envafolimab and Doxorubicin | 18 months | Determine the ORR of envafolimab, YH001 and doxorubicin by RECIST 1.1 by investigator assessment in patients who have not received immune checkpoint inhibitors or doxorubicin with subtypes of advanced or metastatic soft tissue sarcoma. |
| Phase 2: Determine the objective response rate (ORR) of YH001 in combination with Envafolimab | 22 months | Determine the ORR of envafolimab and YH001 by RECIST 1.1 by investigator in patients with subtypes of advanced or metastatic soft tissue sarcoma who have not received immune checkpoint inhibitors. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Phase 1: Assessment of antitumor activity | 8 months | Assess objective response rate (ORR) of YH001 by investigator using RECIST 1.1 when combined with envafolimab or envafolimab/doxorubicin combination in patients with advanced or metastatic sarcoma. |
| Phase 2: Determine the disease control rate (DCR) | 22 months | Determine the Disease Control Rate of envafolimab, YH001 and doxorubicin or envafolimab and YH001 in patients with advanced or metastatic sarcoma. |
| Phase 2: Determine duration of response (DOR) | 22 months | Determine the Duration of Response of envafolimab, YH001 and doxorubicin or envafolimab and YH001 in patients with advanced or metastatic sarcoma. |
| Phase 2: Determine Progression Free Survival (PFS) | 22 months | Determine Progression Free Survival of envafolimab, YH001 and doxorubicin or envafolimab and YH001 in patients with advanced or metastatic sarcoma. |
| Phase 2: Determine Overall Survival (OS) | 22 months | Determine Overall Survival of envafolimab, YH001 and doxorubicin or envafolimab and YH001 in patients with advanced or metastatic sarcoma. |
| Phase 1: YH001 concentrations | 8 months | Determine YH001 trough concentration when given with envafolimab with or without doxorubicin. |
| Phase 2: Envafolimab concentration | 22 months | Determine envafolimab trough concentration when given with YH001 with or without doxorubicin. |
| Phase 2: Determine the Rate of YH001 Immunogenicity | 22 months | Evaluate the formation of YH001 anti-drug antibodies (ADA). |
| Phase 2: Determine the Rate of Envafolimab Immunogenicity | 22 months | Evaluate the formation of envafolimab anti-drug antibodies (ADA). |
| Phase 2: Type Incidence and Severity of Adverse Events | 25 months | Type, incidence, severity (graded by National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\] Version 5.0), timing, seriousness, and relatedness of AEs and laboratory abnormalities. |
| Phase 2: YH001 concentration | 22 months | Determine YH001 trough concentration when given with envafolimab with or without doxorubicin. |
| Phase 1: Envafolimab concentrations | 8 months | Determine envafolimab trough concentration when given with YH001 with or without doxorubicin. |
| Phase 1: Determine the Rate of YH001 Immunogenicity | 8 months | Evaluate the formation of YH001 anti-drug antibodies (ADA). |
| Phase 1: Determine the Rate of Envafolimab Immunogenicity | 8 months | Evaluate the formation of envafolimab anti-drug antibodies (ADA). |
Countries
United States
Outcome results
None listed